Optimized Lentiviral Vector Production Using Dual-Pseudotyping with VSV-G and Sendai Virus HN Glycoproteins for Enhanced Gene Delivery in Diverse Cell Types.

Bat-Erdene Jargalsaikhan, Masanaga Muto, Masatsugu Ema

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bat-Erdene JargalsaikhanDepartment of Stem Cells and Human Disease Models, Research Center for Animal Life Science, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga, Japan.

Masanaga MutoDepartment of Stem Cells and Human Disease Models, Research Center for Animal Life Science, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga, Japan. mmuto@belle.shiga-med.ac.jp.

Masatsugu EmaDepartment of Stem Cells and Human Disease Models, Research Center for Animal Life Science, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga, Japan. mema@bella.shiga-med.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highly efficient gene delivery using lentiviral vectors is beneficial not only for basic cell science research but also for human gene therapy applications. Lentiviral pseudotyping with vesicular stomatitis virus G (VSV-G) is a commonly used method that enables the transduction of various cell types. However, the low expression of low-density lipoprotein-receptor, the primary receptor of VSV-G, limits the efficiency of lentiviral vector transduction. Sendai virus hemagglutinin-neuraminidase glycoproteins recognize terminal sialic acids on the host cell plasma membrane, facilitating viral entry. Here, we describe methods for lentiviral dual-pseudotyping with VSV-G and Sendai virus hemagglutinin-neuraminidase to broaden viral tropism.

Indexed as

Genetic VectorsGene Transfer TechniquesHN ProteinLentivirusSendai virusViral Envelope ProteinsCell LineHEK293 CellsHumansMembrane GlycoproteinsTransduction, GeneticViral TropismG protein, vesicular stomatitis virusHN ProteinMembrane GlycoproteinsViral Envelope ProteinsDual-pseudotypingHemagglutinin-neuraminidaseLentiviral vectorSendai virusVSV-G

Identifiers

PMID41273640

DOI10.3390/v16060827

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.